Vanguard Capital Management
OKUR

Vanguard Capital Management’s OnKure Therapeutics OKUR Stock Holding History

Vanguard Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.55M Buy
1,437,039
+854,562
+147% +$3.67M ﹤0.01% 3019
2026
Q1 		$2.41M Buy
+582,477
New +$1.8M ﹤0.01% 3299

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Vanguard Capital Management's OKUR Position: Q2 2026 in Review

Vanguard Capital Management increased its OnKure Therapeutics (OKUR) stake by 147% in Q2 2026, buying an estimated $3.67M and bringing the position to 1,437,039 shares worth $6.55M. The position accounts for ﹤0.01% of the portfolio, ranked #3019.

Vanguard Capital Management first reported a position in OKUR in Q1 2026 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Vanguard Capital Management held 1,437,039 shares of OnKure Therapeutics worth $6.55M as of Q2 2026.
  • Vanguard Capital Management bought 854,562 OnKure Therapeutics shares in Q2 2026, an estimated $3.67M.
  • OnKure Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3019 holding.
  • Vanguard Capital Management first reported a position in OnKure Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.